Karolinska Development’s portfolio company Biosergen presents positive results from phase 1 study of drug candidate to treat systemic fungal infection
STOCKHOLM, Sweden, March 13, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Biosergen has presented positive results from a clinical phase 1 study of its drug candidate BSG005, which is being developed as a treatment of fungal infection mucormycosis. The result gives hope for a change in the treatment paradigm of patients with invasive fungal infections.
The double-blinded, placebo-controlled clinical phase 1 study was conducted in Australia. The study included both a single ascending dose (SAD) and a multiple ascending dose (MAD) part, and the results showed that BSG005 was safe and well tolerated. No serious adverse events were reported and, importantly, there was no negative safety signal on kidney and liver parameters.
Mucormycosis, also known as black fungus, is a persistent and difficult-to-treat systemic fungal infection causing high mortality rates and the need for new efficacious and safe antifungal treatments is high. Biosergen’s lead candidate drug BSG005 is an antifungal compound that has previously been shown in toxicological studies to be safe, making it a well-positioned alternative to standard-of-care drugs, such as Amphotericin B and Ambisome.
“This satisfactory safety profile supports further development of our portfolio company Biosergen’s drug candidate BSG005. We look forward to the planned phase 2 study in patients with invasive fungal infection who currently have limited options for effective and safe treatments,” says Viktor Drvota, CEO, Karolinska Development.
Karolinska Development's shareholding in Biosergen, through ownership by KDev Investments, amounts to 2%.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: email@example.com
Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: firstname.lastname@example.org
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patient’s lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
ResMed Chief Administrative Officer and Global General Counsel to Retire30.3.2023 22:05:00 CEST | Press release
ResMed to conduct an internal search for a successor general counselAmy Wakeham appointed Chief Communications and Investor Relations Officer, will join ResMed’s executive leadership team SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) announced today that David Pendarvis, chief administrative officer, global general counsel, and secretary, plans to retire, effective June 30, 2023. He will remain in a consulting role with ResMed through December 31, 2023. ResMed will conduct an internal search for the successor to Pendarvis’ legal roles and expects to name a new global general counsel and secretary well ahead of David’s retirement date to ensure a smooth and seamless transition. Amy Wakeham, ResMed’s current Vice President of Corporate Communications & Investor Relations, has been appointed Chief Communications and Investor Relations Officer to succeed Pendarvis in his role leading corporate public affairs; she will report to the Office of the CEO and will jo
The New Zealand Qualifications Authority and World Education Services Partner on Qualifications Recognition for Migrants with International Education30.3.2023 22:00:00 CEST | Press release
WELLINGTON, New Zealand, March 30, 2023 (GLOBE NEWSWIRE) -- The New Zealand Qualifications Authority (NZQA) and World Education Services (WES) have signed an agreement to streamline qualifications assessment for migrants to New Zealand who hold credentials from another country. Under the agreement, WES will provide qualification verification services to immigration applicants to New Zealand. “NZQA is delighted to work with WES to ensure a more efficient process for recognising the educational qualifications of those who want to make New Zealand home,” said NZQA Chief Executive Dr Grant Klinkum. “WES has been verifying academic credentials for decades, and we’ll leverage this experience to the benefit of New Zealand and our newest residents.” The new WES Global Records Verification Report for NZQA is designed to expedite services for individuals who qualify for resident visas under the country’s skilled migrant category. This is part of a broader push to strengthen the nation’s economy.
LEADING EDGE MATERIALS ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD WEDNESDAY, APRIL 26, 202330.3.2023 22:00:00 CEST | Press release
LEADING EDGE MATERIALS ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD WEDNESDAY, APRIL 26, 2023 Vancouver, March30, 2023 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Corporation”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) (FRA: 7FL) announces that its Annual General Meeting of Shareholders (the “Meeting”) will be held at 14th Floor, 1040 West Georgia Street, Vancouver, British Columbia, V6E 4H1 on Wednesday, April 26, 2023, at 9:00 am (Vancouver Time), for the following purposes: To receive the Chief Executive Officer’s Report to the shareholders of the Corporation; To receive and consider the financial statements of the Corporation as at and for the year ended October 31, 2022, together with the report of the auditors thereon; To fix the number of directors of the Corporation to be elected at the Meeting; To elect the directors of the Corporation for the ensuing year; To appoint the auditors of the Corporation for the ensuing year and to authorize t
Leading Edge Materials CEO's Report fo the Shareholders30.3.2023 22:00:00 CEST | Press release
LEADING EDGE MATERIALS CEO’S REPORT TO THE SHAREHOLDERS Stockholm, March 30, 2023 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) (FRA: 7FL) provides a letter from the Chief Executive Officer. CEO’S REPORT TO THE SHAREHOLDERS The past year has not been short of geopolitical turbulence and macro-economic challenges. As the pandemic crisis has subsided, the war in Ukraine, rising inflation and recent bank failures have added to the tension. And of course, the impacts of climate change remain a high priority on political agendas. Our vision, materials for change, is right in the middle of these societal challenges. A change in the energy system towards renewables and energy storage, electrified mobility solutions and resilient and sustainable supply-chains will need new materials and new sources for those materials. This is where the projects we have and the work we do on them becomes critically important. G
Referat af ordinær generalforsamling i Totalbanken A/S30.3.2023 21:20:00 CEST | Press release
Totalbanken A/S har afholdt ordinær generalforsamling torsdag den 30. marts 2023. Dagsorden ifølge vedtægterne. Forslag fra bestyrelsen om forlængelse af bemyndigelse til kapitaludvidelse i vedtægternes § 4 og ny § 7, der giver bestyrelsen mulighed for at afvikle fuldstændig elektroniske generalforsamlinger, blev vedtaget. Attachment 2023-05 Referat af ordinær generalforsamling 20230330